Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission.
Giacomelli R, Caporali R, Ciccia F, Colafrancesco S, Dagna L, Govoni M, Iannone F, Leccese P, Montecucco C, Pappagallo G, Pistone G, Priori R, Ruscitti P, Sfriso P, Cantarini L; Expert Panel. Giacomelli R, et al. Among authors: iannone f. Autoimmun Rev. 2023 Dec;22(12):103400. doi: 10.1016/j.autrev.2023.103400. Epub 2023 Jul 22. Autoimmun Rev. 2023. PMID: 37482365 Review.
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G; GISEA (Gruppo Italiano per lo Studio delle Early Arthritis). Iannone F, et al. Ann Rheum Dis. 2007 Feb;66(2):249-52. doi: 10.1136/ard.2006.058776. Epub 2006 Jul 12. Ann Rheum Dis. 2007. PMID: 16837489 Free PMC article.
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G. Atzeni F, et al. Among authors: iannone f. Autoimmun Rev. 2012 Dec;12(2):225-9. doi: 10.1016/j.autrev.2012.06.008. Epub 2012 Jul 13. Autoimmun Rev. 2012. PMID: 22796281
Delights and let-downs in the management of tumor necrosis factor receptor-associated periodic syndrome: the canakinumab experience in a patient with a high-penetrance T50M TNFRSF1A variant.
Cantarini L, Lopalco G, Vitale A, Caso F, Lapadula G, Iannone F, Galeazzi M, Rigante D. Cantarini L, et al. Among authors: iannone f. Int J Rheum Dis. 2015 May;18(4):473-5. doi: 10.1111/1756-185X.12521. Epub 2014 Dec 18. Int J Rheum Dis. 2015. PMID: 25522898 No abstract available.
503 results